BI 1701963 + BI 3011441

**BI 1701963 + BI 3011441** is an oral combination regimen under investigation for the treatment of advanced cancers harboring KRAS mutations, including solid tumors such as non-small cell lung cancer (NSCLC) and colorectal cancer. BI 1701963 acts as a selective inhibitor of SOS1 (Son of Sevenless 1), thereby blocking the activation of RAS proteins, including KRAS, upstream in the signaling cascade. BI 3011441 is a selective inhibitor of RAF kinases (most likely a pan-RAF inhibitor), targeting downstream signaling in the RAS-RAF-MEK-ERK pathway. The combination is designed to prevent KRAS activation and block downstream RAF-mediated signaling, which are both required for the proliferation and survival of KRAS-mutant cancer cells. The developers, Boehringer Ingelheim, are evaluating the safety, tolerability, optimal dosing, and preliminary efficacy of this combination in Phase 1 clinical trials for patients whose cancers have not responded to standard therapies[1][2][3][5].